Gefitinib, a targeted therapy, has transformed the treatment of non-small cell lung cancer (NSCLC) by specifically inhibiting the epidermal growth factor receptor (EGFR) mutation, which drives tumor growth. Unlike traditional chemotherapy, Gefitinib offers a personalized approach, effectively slowing disease progression ...